Propositional debate on biosimilar enoxaparin in Brazil.
Generics, chemisimilars and biosimilars: is clinical testing fit for purpose?
Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars.
Regulatory forum opinion piece: differences between protein-based biologic products (biotherapeutics) and chemical entities (small molecules) of relevance to the toxicologic pathologist.
Characterization and comparison of commercially available TNF receptor 2-Fc fusion protein products.
The emergence of biosimilar insulin preparations--a cause for concern?
Biosimilars: what clinicians should know.